Title: Talaporfin
CAS Registry Number: 110230-98-3
CAS Name: N-[[(7S,8S)-3-Carboxy-7-(2-carboxyethyl)-13-ethenyl-18-ethyl-7,8-dihydro-2,8,12,17-tetramethyl-21H,23H-porphin-5-yl]acetyl]-L-aspartic acid
Additional Names: (2S,3S)-18-carboxy-20-[N-(S)-1,2-dicarboxyethyl]carbamoylmethyl-13-ethyl-3,7,12,17-tetramethyl-8-vinylchlorin-2-propanoic acid; mono-L-aspartyl chlorin e6; NPe6
Molecular Formula: C38H41N5O9
Molecular Weight: 711.76
Percent Composition: C 64.12%, H 5.81%, N 9.84%, O 20.23%
Literature References: Semisynthetic derivative of chlorin e6, q.v. Photosensitizer activated at 664 nm by laser or light-emitting diode-based light infusion device. Causes irreversible tumor blood vessel closure. Prepn: J. C. Bommer, B. F. Burnham, EP 168831; eidem, US 4675338 (1986, 1987 both to Nippon Petrochemicals). Photophysical properties: J. D. Spikes, J. C. Bommer, J. Photochem. Photobiol. B 17, 135 (1993); L. Li et al., ibid. 67, 51 (2002). Chemical and NMR structural studies: S. Gomi et al., Heterocycles 48, 2231 (1998). Safety assessment in treatment of refractory solid tumors: R. A. Lustig et al., Cancer 98, 1767 (2003). Clinical evaluation in lung cancer: H. Kato et al., Lung Cancer 42, 103 (2003).
Properties: Dark blue-green powder. Sol in water. Absorption max (phosphate buffer, pH 7.4): 400, 654 nm (e 180000, 40000). Absorption max (p-dioxane): 401.7, 663.5 nm (EmM 111, 38). Hygroscopic and light sensitive. Store under vacuum; protect from light.
Absorption maximum: Absorption max (phosphate buffer, pH 7.4): 400, 654 nm (e 180000, 40000); Absorption max (p-dioxane): 401.7, 663.5 nm (EmM 111, 38)
 
Derivative Type: Tetrasodium salt
CAS Registry Number: 220201-34-3
Additional Names: Talaporfin sodium
Manufacturers' Codes: LS-11; ME-2906
Trademarks: Laserphyrin (Meiji)
Molecular Formula: C38H37N5Na4O9
Molecular Weight: 799.69
Percent Composition: C 57.07%, H 4.66%, N 8.76%, Na 11.50%, O 18.01%
 
Therap-Cat: Antineoplastic (photosensitizer).
Keywords: Antineoplastic (Photosensitizer).

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（2009102105440429.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------

 注意：该药品储存于2-8度

Light Sciences今日宣布，其先导化合物LS11(在日本称为Laserphyrin)的授权公司——Meiji Seika获得了日本厚生省Pharmaceutical Affairs and Food Sanitation Council的批准推荐。该药物将获准用于早期支气管癌的光动力疗法。

　　日本政府对全球第二大保健市场决策的出台，是缘于Light Sciences成功地完成了其先导化合产品Litx(TM)用于实体癌晚期患者的第一和第二阶段研究。Litx System关键成分之
一就是具有光活性的LS11药物。

　　Light Sciences的总裁兼首席执行官Albert Luderer博士表示：“我们的先导药物在日本获得批准推荐之时，正值我们的肿瘤学项目第二阶段在全球启动之际。LS11杰出的安全性使我们深受鼓舞。我们相信这一里程碑式的政府决策将为Litx下一阶段的评估树立积极的基调。”

　　Light Sciences在2000年初从日本石化公司(Nippon Petrochemicals)和日本明治制果株式会社(Meiji Seika Kaisha)获得了LS11的授权，同时获得了开发、制造和出售该化合物，用于日本以外世界其他地区的光力学治疗的多种疗法应用的专有权。

　　Litx以新一代光活性药物为基础，这种药物在治疗场所由微小且成本低廉的发光二极管为其制造并传输光能。Litx主要用于治疗局部疾病，并初步用于对手术、放疗或化疗等疗法均告失败的实体瘤患者的研究。

　　美国癌症学会(American Cancer Society)预测，今年将有超过550,000名病情已到达这种程度的癌症患者死亡，即每天死亡1,500多人。Litx还被作为针对心血管疾病的介入疗法正在进行前临床实验，而针对眼疾的第一阶段研究也正在进行中。

注意：该药品储存于2-8度

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（2009102105440429.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------